加载中
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
前收盘价
US$1.23
−US$0.11 · -8.21%
盘后
US$1.2582
+US$0.0282 · +2.29%
10月12日 19:58 ET
盘中时间采用ET。市场数据可能有所延迟。
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
日内区间
当前US$1.23
52周区间
当前US$1.23
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
48
合理估值
情绪
41
多空交织
风险
69
高风险
动量
30
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
日内区间
当前US$1.23
52周区间
当前US$1.23
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 250.1万 USD | — | 250.1万 USD | — | — |
| 毛利 | −250.1万 USD | — | −250.1万 USD | — | — |
| 研究与开发 | 1021.1万 USD | 1696.2万 USD | 1682.7万 USD | 1406.2万 USD | 734.7万 USD |
| 销售、一般及管理费用 | 965万 USD | 1263.7万 USD | 1351万 USD | 1445.9万 USD | 730.6万 USD |
| 营业费用 | 1736万 USD | 3043.7万 USD | 2783.6万 USD | 2852.1万 USD | 1465.3万 USD |
| 利息收入 | 42.1万 USD | 23万 USD | — | — | — |
| 折旧和摊销 | 250.1万 USD | 265.5万 USD | 250.1万 USD | 110.3万 USD | 78.8万 USD |
| 营业利润 | −1986.1万 USD | −3043.7万 USD | −3033.7万 USD | −2852.1万 USD | −1465.3万 USD |
| 净利润 | −1944万 USD | −3043.7万 USD | −3000.7万 USD | −2852.1万 USD | −1465.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.00
上涨空间 225.20%评级样本有限，仅4项
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
